What will you answer when a potential investor asks you how and when they’ll get a return on their investment?
Whatever your company’s ambitions are in terms of Initial Public Offering (IPO), Mergers & Acquisitions (M&A) or licensure, you will probably want to keep your options open in the early stages of your company’s development. Have you identified your long-term exit strategy, including your strategic endgame and a plan for getting there?
During this interactive session Johnson & Johnson Innovation aims to provide a no-nonsense guide to key aspects of exits through M&A, focused on early-stage life sciences and medtech companies with deep IP.
The programme will be led by experts from Allen & Overy’s market-leading technology team who have deep experience in Mergers & Acquisitions (M&A) in different global ecosystems including Silicon Valley. They will share insights into:
- what to expect from acquirers and investors;
- how to create a strong position for negotiations;
- approaches you might expect from buyers;
- differences between the USA, UK and EU;
- common pitfalls and how to avoid them.
10:30 CEST Registration open for in-person attendees
11:00 CEST Introduction by Johnson & Johnson Innovation
Niels Wheeler | Innovation Activation Manager, Johnson & Johnson Innovation
11:10 CEST Workshop by Allen & Overy
Will Samengo-Turner | Partner, Allen & Overy
Eimear Coady | Senior Associate, Allen & Overy
12:30 CEST Lunch break (basic lunch will be provided for in-person attendees)
13:30 CEST One-to-one mentoring meetings with selected companies
17:00 CEST Event Close
Following the workshop, Allen & Overy will provide one-to-one mentoring sessions (25 minutes each) for selected companies. Please see here for more information including application details.
Source: Johnson & Johnson